NTT-002

Summary

NTT-002 is a nanoformulation of irinotecan-loaded mesoporous silica nanoparticles (MSNs) developed for the treatment of highly metastatic colorectal cancer. This advanced nanomedicine is designed to suppress both primary tumor growth and metastatic progression, offering a promising approach for treating aggressive cancers.

 

Advantages of NTT-002

• Maintains API in its active therapeutic form
• Enables tumor-targeted delivery with reduced systemic toxicity
• Demonstrates inhibition of cancer metastasis
• Significantly improves overall survival
 

Efficacy in Inhibiting Tumor Growth and Metastasis

100% of mice treated with NTT-002 survived to the end of the study, exhibiting complete tumor regression and no detectable metastases.

 

Details of MSN’s unique anti-metastatic activity are available in ACS Appl. Mater. Interfaces 2024, 16, 61787